Note 4 - Stockholders' Equity, Stock Options and Warrants (Details Textual)											1 Months Ended				2 Months Ended	3 Months Ended	4 Months Ended	9 Months Ended	12 Months Ended
	Sep. 14, 2020 USD ($) $ / shares shares	Jul. 01, 2020 USD ($) shares	Jun. 12, 2020 shares	May 27, 2020 USD ($) shares	May 08, 2020 USD ($) $ / shares shares	Apr. 21, 2020 USD ($) $ / shares shares	Apr. 04, 2020 shares	Mar. 18, 2020 $ / shares shares	Oct. 29, 2019 $ / shares	Oct. 24, 2019 USD ($) shares	Jun. 30, 2020 USD ($) $ / shares shares	May 31, 2020 shares	Mar. 18, 2020 USD ($) $ / shares shares	Apr. 30, 2019 shares	Feb. 28, 2021 shares	Mar. 31, 2020 shares	Sep. 30, 2019 USD ($) shares	Sep. 30, 2021	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Aug. 17, 2021 $ / shares shares	Aug. 10, 2021 shares	Jun. 30, 2021 shares	Sep. 23, 2020 $ / shares shares	Jan. 31, 2020 USD ($)	Jul. 15, 2019 USD ($)
Common Stock, Shares Authorized (in shares)																			200,000,000	100,000,000	200,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.01																		$ 0.01	$ 0.01	$ 0.01			$ 0.01
Sale of Stock, Agent Placement Fee, Percent of Gross Proceeds															7.50%
Sale of Stock, Management Fee, Percent of Gross Proceeds															1.00%
Proceeds from Warrant Exercises | $																			$ 4,513,871	$ 1,935,855
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $																			0	5,057,919
Debt Instrument, Face Amount | $																			0	4,676,755
Fixed Assets Acquired for Notes Receivable and Common Stock | $																			0	2,962,767
Fair Value Adjustment of Warrants | $																			$ (164,902)	$ (1,765,907)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number (in shares)																			949,615	977,420
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares																			$ 5.27	$ 5.29
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year)																			8 years 1 month 20 days	8 years 9 months 3 days
Class of Warrant or Right Number of Warrants Vested and Exercisable (in shares)																			31,725,118	7,353,376
Share-based Payment Arrangement, Expense | $																			$ 146,714	$ 780,269
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $																			$ 70,324
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)																			19 years
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio									0.1
Other Capitalized Property Plant and Equipment [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total | $				$ 1,492,500
Asset Purchase Agreement with InventaBiotech and Its Subsidiaries, Soluble and BioDeth [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)				125,000
Fixed Assets Acquired for Notes Receivable and Common Stock | $				$ 1,290,000
Asset Purchase Shares Issued Shares Escrow Deposit To Be Released Upon Six Months Anniversary Of Closing (in shares)				25,000
Asset Purchase Shares Issued, Shares Escrow Deposit To Be Released Upon Nine Months Anniversary Of Closing (in shares)				25,000
Business Acquisition, Right to Reclaim, Number of Shares (in shares)				10,000
Asset Purchase Agreement With Quantitative Medicine [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		954,719
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | $		$ 1,470,267
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow (in shares)		477,359
Asset Purchase Agreement With Quantitative Medicine [Member] | Carnegie Mellon University [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		207,144
Conversion of Promissory Note Into Common Stock [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares						$ 1.43
DrSchwartz Notes [Member]
Debt Instrument, Face Amount | $						$ 2,115,000																			$ 2,115,000	$ 1,920,000
DrSchwartz Notes [Member] | Conversion of Promissory Note Into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)						1,583,481
Conversion from Series D Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)							3,500,000
Conversion of Stock, Shares Issued (in shares)							350,004
Conversion from Series E Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)												207.7				50
Conversion of Stock, Shares Issued (in shares)			1,257,416													141,191
Conversion of Stock, Shares Issued, Percentage of Outstanding Shares			11.80%									0.05686%
Preferred Stock, Shares Outstanding, Ending Balance (in shares)			207.7
Series D Preferred Stock [Member]
Preferred Stock, Shares Issued, Total (in shares)														3,500,000
Convertible Preferred Stock, Conversion Rate														10
Series E Convertible Preferred Stock [Member]
Convertible Preferred Stock, Conversion Rate																	0.056857
Stock Issued During Period, Shares, Convertible Preferred Shares Issued (in shares)																	258
Preferred Stock, Beneficial Conversion Feature | $																	$ 289,935
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																			$ 22.50
Maximum [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)																			3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)																			10 years
Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)																		3 years
Stock Incentive Plan 2012 [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)																						3,250,000	1,500,000
Investor Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)																			5,269,059
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																			$ 0.86
Proceeds from Warrant Exercises | $																			$ 4,513,871
Placement Agent Warrants [Member]
Sale of Stock, Placement Agent, Warrants Assigned, Number of Securities Called by Warrants, Percent of Shares Sold															7.50%
Class of Warrant or Right, Exercise Price of Warrants or Rights, Percent of Stock Price															125.00%
Warrants issued with Private Placement [Member]
Warrants and Rights Outstanding, Term (Year)					5 years 6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 1.45			$ 0.001					$ 0.001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					1,396,826			1,390,166					1,390,166
Price of Warrant (in dollars per share) | $ / shares								$ 2.12
Proceeds from Issuance or Sale of Equity, Total | $					$ 2,200,001
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $					$ 1,930,100
Shares Issued, Price Per Share (in dollars per share) | $ / shares					$ 1.575
Series A Warrants [Member]
Warrants and Rights Outstanding, Term (Year)								5 years 6 months					5 years 6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 1.88					$ 1.88
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								1,650,166					1,650,166
Series B Warrants [Member]
Warrants and Rights Outstanding, Term (Year)								2 years					2 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 1.88					$ 1.88
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								1,650,166					1,650,166
Prefunded Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 0.0001					$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								1,390,166					1,390,166
Price of Warrant (in dollars per share) | $ / shares													$ 2.12
June 2020 Warrant [Member]
Warrants and Rights Outstanding, Term (Year)											5 years 6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 1.80													$ 1.88
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																								1,396,826
Class of Warrant or Right, Exercise Price of Warrants or Rights, Amended Price (in dollars per share) | $ / shares																								$ 0.8457
Class Of Warrant Or Right, Purchase Price Per Warrant (in dollars per share) | $ / shares											$ 0.125
Class of Warrant or Right, Percentage of Shares Issued Pursuant to Exercise of Existing Warrant											100.00%
Proceeds from Issuance and Exercise of Warrants | $											$ 2,130,701
Proceeds from Issuance and Exercise of Warrants, Net | $											$ 1,865,800
Warrant Issued in Connection With May 2020 Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 1.45
Class of Warrant or Right Issued During Period (in shares)											1,396,826
Warrants Issued in Connection With Helomics Acquisition [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.845								$ 10.00
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,424,506
Fair Value Adjustment of Warrants | $	$ 554,287
Registered Direct Offerings [Member]
Number of Warrants Issued to Each Investor, Per Two Shares of Stock Purchased (in shares)															1
Stock Issued During Period, Value, New Issues | $																			15,012,492
Registered Direct Offerings [Member] | Investor Warrants [Member]
Warrants and Rights Outstanding, Term (Year)															5 years 6 months
Registered Direct Offerings [Member] | Placement Agent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)															5 years
Private Placement [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares					$ 0.01
Number of Warrants Issued to Each Investor, Per Two Shares of Stock Purchased (in shares)															1
Stock Issued During Period, Shares, New Issues (in shares)					1,396,826			260,000
Stock Issued During Period, Value, New Issues | $																			16,064,739
Sale of Stock, Price Per Share (in dollars per share) | $ / shares								$ 2.121					$ 2.121
Proceeds from Issuance or Sale of Equity, Total | $													$ 3,498,612
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $													$ 3,127,818
Private Placement [Member] | Placement Agent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)															5 years 6 months
June 2021 Offering [Member]
Stock Issued During Period, Value, New Issues | $																			$ 19,446,296
June 2021 Offering [Member] | Placement Agent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)															3 years
Equity Line Purchase Agreement [Member]
Issuance or Sale of Equity, Can Be Raised | $										$ 15,000,000
Stock Issued During Period, Shares, New Issues (in shares)										104,651									647,504	4,231,073
Stock Issued During Period, Value, New Issues | $										$ 450,000									$ 675,590	$ 4,891,348
Sale of Stock, Remaining Available Balance | $																			$ 9,113,829